<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Aqr Alternative Risk Premia Fund Class N — News on 6ix</title>
    <link>https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n</link>
    <description>Latest news and press releases for Aqr Alternative Risk Premia Fund Class N on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/aqr-alternative-risk-premia-fund-class-n" rel="self" type="application/rss+xml" />
    <item>
      <title>Twin Disc Announces Details of Fiscal 2026 Third Quarter Earnings Release, Webcast, and Conference Call</title>
      <link>https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/twin-disc-announces-details-of-fiscal-2026-third-quarter-earnings-release-webcast-and-conference-call-4</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/twin-disc-announces-details-of-fiscal-2026-third-quarter-earnings-release-webcast-and-conference-call-4</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>MILWAUKEE, April 22, 2026 (GLOBE NEWSWIRE) -- Twin Disc, Inc. (NASDAQ: TWIN), today announced that it will release its fiscal 2026 third-quarter results at</description>
    </item>
    <item>
      <title>Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting</title>
      <link>https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/immutep-announces-abstract-accepted-for-presentation-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting-1</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/immutep-announces-abstract-accepted-for-presentation-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting-1</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy</description>
    </item>
    <item>
      <title>The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform</title>
      <link>https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/the-beauty-health-company-announces-corporate-rebrand-to-skinhealth-systems-reflecting-evolution-into-a-clinically-driven-science-backed-medical-aesthetics-platform-10</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/the-beauty-health-company-announces-corporate-rebrand-to-skinhealth-systems-reflecting-evolution-into-a-clinically-driven-science-backed-medical-aesthetics-platform-10</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>The Company will continue trading on the Nasdaq Capital Market under the ticker symbol “SKIN” LONG BEACH, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- The</description>
    </item>
    <item>
      <title>TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028</title>
      <link>https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/tuhura-biosciences-announces-dollar50-million-credit-facility-and-royalty-transaction-extending-anticipated-cash-runway-into-2028-2</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/tuhura-biosciences-announces-dollar50-million-credit-facility-and-royalty-transaction-extending-anticipated-cash-runway-into-2028-2</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement</description>
    </item>
    <item>
      <title>Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®</title>
      <link>https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/labcorp-launches-fda-approved-companion-diagnostic-to-identify-patients-with-ovarian-cancer-eligible-for-keytrudar-3</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/labcorp-launches-fda-approved-companion-diagnostic-to-identify-patients-with-ovarian-cancer-eligible-for-keytrudar-3</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the</description>
    </item>
    <item>
      <title>AerCap Publishes Corporate Responsibility Report for 2025</title>
      <link>https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/aercap-publishes-corporate-responsibility-report-for-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-alternative-risk-premia-fund-class-n/news/aercap-publishes-corporate-responsibility-report-for-2025-1</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>DUBLIN, April 22, 2026 /PRNewswire/ -- AerCap Holdings N.V. (&quot;AerCap&quot; or the &quot;Company&quot;) (NYSE: AER) today announced the publication of its Corporate</description>
    </item>
  </channel>
</rss>